Skip to main content
SpringerLink
Log in

Infantile Hämangiome

Manifestationsformen, Therapie, Differenzialdiagnosen

Infantile hemangioma

Clinical manifestation, treatment, and differential diagnoses

  • Leitthema
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

A Leserforum to this article was published on 15 November 2023

A Leserforum to this article was published on 15 November 2023

Zusammenfassung

Infantile Hämangiome sind mit einer Prävalenz von 4 % die häufigsten vaskulären Tumoren bei Kindern und zeigen eine charakteristische Wachstumsdynamik. Zur Vermeidung einer Fehlbehandlung müssen sie von anderen vaskulären Tumoren (Granuloma pyogenicum und kaposiformes Hämangioendotheliom) sowie vaskulären Fehlbildungen abgegrenzt werden. Mittel der 1. Wahl für die Behandlung komplizierter Hämangiome (15 %) ist Propranolol; orale Gaben von 2 mg/kgKG und Tag über mindestens 6 Monate sind bei drohender Obstruktion (Auge und Nase), Ulzeration oder permanenter Entstellung indiziert.

Abstract

With an incidence of approximately 4% infantile hemangiomas are the most common vascular tumors in children and show characteristic growth dynamics. In order to avoid erroneous treatment, they need to be differentiated from other vascular tumors (granuloma pyogenicum and kaposiform hemangioendothelioma) and vascular malformations. Of all infantile hemangiomas 85% are uncomplicated and undergo spontaneous resolution starting towards the end of the first year of life. First-line treatment for complicated infantile hemangiomas (15%), i.e. those with imminent obstruction (eyes and nose), ulceration or permanent disfigurement, is oral propranolol (2 mg/kg BW and day for at least 6 months).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9
Abb. 10

Literatur

  1. Léautè-Labrèze C, Harper JI, Hoeger PH (2017) Infantile Haemangioma. Lancet 390:85–94

    Article  PubMed  Google Scholar 

  2. Schoch JJ, Hunjan MK, Anderson KR et al (2018) Temporal trends in prenatal risk factors for the development of infantile hemangiomas. Pediatr Dermatol 35:787–791

    Article  PubMed  PubMed Central  Google Scholar 

  3. Drolet BA, Swanson EA, Frieden IJ, Hemangioma Investigator Group (2008) Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 153:712–715

    Article  PubMed  Google Scholar 

  4. de Jong S, Itinteang T, Withers AH et al (2016) Does hypoxia play a role in infantile hemangioma? Arch Dermatol Res 308:219–227

    Article  PubMed  Google Scholar 

  5. Smith CJF, Friedlander SF, Gurna M et al (2017) Infantile hemangiomas: an updated review on risk factors, pathogenesis and treatment. Birth Defects Res 109:809–881

    Article  CAS  PubMed  Google Scholar 

  6. Colonna V, Resta L, Napoli A, Bonifazi E (2010) Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br J Dermatol 162:208–209

    Article  CAS  PubMed  Google Scholar 

  7. Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ (2006) Patterns of infantile hemangioma: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 117:698–703

    Article  PubMed  Google Scholar 

  8. Haggstrom AN, Baselga E, Chamlin SL et al (2018) Localized infantile hemangiomas of the face and scalp: predilection for the midline and periorbital and perioral skin. Pediatr Dermatol 35:774–779

    Article  PubMed  Google Scholar 

  9. Höger P (2021) Kinderdermatologie, 4. Aufl. Thieme, Stuttgart

    Google Scholar 

  10. O’Brien KF, Shah SD, Pope E et al (2019) Late growth of infantile hemangiomas in children 〉3 years of age: a retrospective study. J Am Acad Dermatol 80:493–449

    Article  PubMed  Google Scholar 

  11. Sun Y, Qiu F, Hu C et al (2022) Hemangioma endothelial cells and hemangioma stem cells in infantile hemangioma. Ann Plast Surg 88:244–249

    Article  CAS  PubMed  Google Scholar 

  12. Reimer A, Hoeger PH (2016) Lesion morphology in multifocal infantile hemangiomas. Pediatr Dermatol 33:621–626

    Article  PubMed  Google Scholar 

  13. Ji Y, al Chen Ket SY (2021) Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: a multicenter prospective study. J Am Acad Dermatol 84:1378–1384

    Article  PubMed  Google Scholar 

  14. Rialon KL, Murillo R, Fevurly RD et al (2015) Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. J Pediatr Surg 50:837–841

    Article  PubMed  Google Scholar 

  15. Martin JM, Sanchez S, González V et al (2019) Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Pediatr Dermatol 36:125–131

    Article  PubMed  Google Scholar 

  16. Bessis D, Bigorre M, Labrèze C (2015) Reticular infantile hemangiomas with minimal or arrested growth associated with lipoatrophy. J Am Acad Dermatol 72:828–833

    Article  PubMed  Google Scholar 

  17. Reimer A, Fliesser M, Hoeger PH (2016) Anatomical patterns of infantile hemangioma (IH) of the extremities (IHE). J Am Acad Dermatol 75:556–563

    Article  PubMed  Google Scholar 

  18. Luu M, Frieden IJ (2016) Infantile hemangiomas and structural anomalies: PHACE and LUMBAR syndrome. Semin Cutan Med Surg 35:117–123

    Article  PubMed  Google Scholar 

  19. Schmid F, Reipschlaeger M, Leenen A, Hoeger PH (2019) Risk of associated cerebrovascular anomalies in children with segmental facial haemangiomas. Br J Dermatol 181:1334–1335

    Article  CAS  PubMed  Google Scholar 

  20. Garzon MC, Epstein LG, Heyer GL et al (2016) PHACE syndrome: consensus-derived diagnosis and care recommendations. J Pediatr 178:24–33.e2

    Article  PubMed  PubMed Central  Google Scholar 

  21. Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften (AWMF). S2k-Leitlinie Infantile Hämangiome im Säuglings- und Kleinkindesalter. Reg.-Nr. 006-100, gültig bis 31. Okt. 2023

  22. Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163:269–274

    Article  CAS  PubMed  Google Scholar 

  23. Li HH, Lou Y, Zhang RR et al (2019) Propranolol accelerates Hemangioma stem cell transformation into adipocyte. Ann Plast Surg 83:e5–e13

    Article  CAS  PubMed  Google Scholar 

  24. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al (2015) A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372:735–746

    Article  PubMed  Google Scholar 

  25. Wedgeworth E, Glover M, Irvine AD et al (2016) Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol 174:594–601

    Article  CAS  PubMed  Google Scholar 

  26. Hengst M, Oelert M, Hoeger PH (2015) Blood pressure monitoring during the induction and maintendance period of propranolol therapy for complicated infantile hemangiomas: a prospective study of 109 infants. Pediatr Dermatol 32:802–807

    Article  PubMed  Google Scholar 

  27. Schmid F, Hoeger PH (2022) Propranolol response in patients with segmental versus focal facial hemangiomas: a retrospective case-control study. J Am Acad Dermatol 87:490–491

    Article  CAS  PubMed  Google Scholar 

  28. Bayart CB, Tamburro JE, Vidimos AT et al (2017) Atenolol versus propranolol for treatment of infantile Hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol 34:413–421

    Article  PubMed  Google Scholar 

  29. Bernabeu-Wittel J, Narváez-Moreno B, de la Torre-García JM et al (2015) Oral nadolol for children with infantile Hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol 32:853–857

    Article  PubMed  Google Scholar 

  30. Frommelt P, Juern A, Siegel D et al (2016) Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma. Pediatr Dermatol 33:405–414

    Article  PubMed  Google Scholar 

  31. Borok J, Gangar P, Admani S et al (2018) Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial. Br J Dermatol 178:e51–e52

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilungen für Pädiatrie und Pädiatrische Dermatologie, Kath. Kinderkrankenhaus Wilhelmstift Hamburg, Liliencronstr. 130, 22149, Hamburg, Deutschland

    Peter H. Höger

  2. Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Henning Hamm

Authors
  1. Peter H. Höger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henning Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter H. Höger.

Ethics declarations

Interessenkonflikt

P.H. Höger hat Honorare für Beratertätigkeiten, Vorträge und die Durchführung von Studien von folgenden Pharmaunternehmen erhalten: 1. Unterstützung klinischer Forschung: AbbVie, Lilly, Mayne, Novartis; 2. Beratung: AbbVie, Novartis, Klinge, Golin; 3. Vortragshonorare: Thieme Verlag, Novartis, Beiersdorf. H. Hamm hat Honorare für Beratertätigkeiten, Vorträge und die Durchführung von Studien von folgenden Pharmaunternehmen erhalten: Allergika, Biogen, InfectoPharm, Lilly, Novartis, Pierre Fabre Dermo Kosmetik.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Henning Hamm, Würzburg

Peter H. Höger, Hamburg

Reinhard Berner, Dresden

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Höger, P.H., Hamm, H. Infantile Hämangiome. Monatsschr Kinderheilkd 171, 410–419 (2023). https://doi.org/10.1007/s00112-023-01736-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-023-01736-4

Schlüsselwörter

Keywords

Search

Navigation